Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
8.39-0.17 (-1.99%)
At close: 04:00PM EDT
8.31 -0.08 (-0.95%)
After hours: 07:29PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Performance Outlook
Previous Close8.56
Open8.64
Bid8.10 x 1100
Ask8.87 x 1800
Day's Range8.31 - 8.70
52 Week Range7.61 - 18.00
Volume2,042,436
Avg. Volume3,046,773
Market Cap1.581B
Beta (5Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BCRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioCryst Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/26/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    BioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success

    RESEARCH TRIANGLE PARK, N.C., March 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today acknowledged the many contributions of Robert A. Ingram, the company’s chairman of the board, who recently passed away. We are very saddened by his loss and our thoughts and prayers go to Bob’s wife Jeanie and his sons Cameron, Michael and Rory. Bob served as a board member since 2015 and chairman since 2017 and played a central role in recruiting highly accomplished board members

  • GlobeNewswire

    CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada

    INTENDED FOR CANADIAN AUDIENCES ONLY RESEARCH TRIANGLE PARK, N.C., March 08, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive recommendation for ORLADEYO® (berotralstat) to be reimbursed for the routine prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. “We are still in

  • GlobeNewswire

    BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., March 02, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 110,400 shares, and restricted stock units (RSUs) covering an aggregate of 51,300 shares, of BioCryst common stock. The options and RSUs were granted as of February 28, 2023 as inducements material to each employee entering into empl

Advertisement
Advertisement